Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cero Therapeutics develops innovative engineered T cell therapies for cancer, focusing on both hematological malignancies and solid tumors. Its platform integrates innate and adaptive immune functions into CER-T cells, targeting tumor-specific antigens like TIM-4-L. The company's lead candidate, CER-1236, aims to enhance tumor clearance via cytotoxic, phagocytic, and antigen presentation mechanisms, leveraging well-established CAR-T manufacturing processes for broad cancer treatment applications.
This description was generated via AI from an annual report. Updated about 1 year ago.